The pharmaceutical company allegedly provided physicians with free units of Hyalgan to induce them to purchase and/or prescribe the drug.
The settlement also resolves allegations that Sanofi submitted false average sales price reports for the knee injection, which failed to account for the free units distributed contingent on Hyalgan purchases.
The government claimed the false ASP reports were used to set reimbursement rates that caused government programs to pay inflated amounts for Hyalgan and a competing product.
More Articles on Pharmaceutical Companies and Settlements:
Amgen Agrees to $762M Fine for Drug Misbranding
Pfizer Reaches $60M Settlement Over Foreign Bribe Allegations
McKesson Settles Allegations of Inflated Drug Prices With $151M
